Pfizer Inc (PFE)

It would not be a top pick. It is more of a marketing engine as opposed to a company that develops drugs. It has made some poor acquisitions and there are better opportunities.

Disappointing since Covid. Great pipeline, good drugs that can become blockbusters. Valuation is 11x forward earnings, 6.5x trailing. Stock is basing around $35 support levels of 2020-21, and he's watching closely. Don't sell now. While you wait, you're getting a pretty decent yield of 4.5%.

Really cheap and pays a good dividend. But earnings keep falling. Are trying to get into the weight-loss space. Wait. Don't add to it.

They accumulated a lot of cash during Covid with their vaccine, but of course demand has fallen. They have a patent cliff in a few years, so they're buying companies to replace their drug pipeline and are developing drugs in-house. Shares have pulled back, so earnings will be negative in coming years. Trades at a decent PE. She may add, but will watch this.

Very good company with volatile earnings.
Strong R & D pipeline.
Not concerned about patent expires.
Trading at cheap price.
Good long term investment.
Inflation act (reduction in pricing) not a worry.

Some earnings growth and resistance from a recession. You need defense as the banks continue to raise rates, as he expects. A good drug pipeline. 11x forward earnings and pays a 4.4% dividend. Hold lots of cash from their Covid sales. 

Possibly a bit more downside before it finds a home. You'll have to watch if it forms the zig-zag thing that he calls a base. Then you can consider doing short-term trading, or wait for a breakout from that base. He wouldn't buy it today.

One of the world's great drug companies. Peaked with Covid vaccine sales, stock's come off. Billions of dollars in potential new drugs in the pipeline. Has its own weight loss drug, though approval is some years away. Won't lose a lot of money, and upside potential is huge. Yield is 4.20%. 

Great business that has performed well.
Federal government blocking recent M&A a concern for shareholders.
Long term, excellent business.
High margins with excellent management team.

They used their sizeable cash flow for acquisitions. The question is have they overpaid. He still likes it but needs to see execution on their increased spending in R&D and M&A.

Passing Covid-19 pandemic negatively affecting business.
Sales not as strong after pandemic ending.
Betting on recovery of sales (not worth taking).
Would not recommenced shares in company right now.
Wait for share price to fall.

They report Tuesday. Are considered a Covid stock. They're buying Seagen for $43 billion so they can build an anti-cancer franchise. They need this. Pfizer has a strong pipeline, but when will they get behind their migraine drug, which was part of an acquisition? They're doing nothing with it.

The problem with these drug companies is that they depend on their drugs coming off-patent, so do they have a pipeline to replace that? Prefers JNJ because it has other businesses to cushion that loss. PFE is defensive and pays a good dividend. Look for M&A developments too. Not trading at a high PE and are well-financed. Healthcare is highly defensive.

Good dividend. Growth rate is pretty negative, but improves from 2023-2025 at close to 14% and 9.5x 2025. At cheap enough levels to start buying. Like the Dogs of the Dow theory. Pan for gold when a name's being ignored, and this is one of those.

Covid earnings are less and he has trimmed a lot. It is now at an attractive price in the low 40's. If you wanted to diversify you could switch half your holdings into Eli Lilly and/or Merck.